EcoDrugPlus

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSBTAG00000002048
Gene Symbol: PTPN11
85 Enzyme and pathways 5 Cross references
267 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSBTAG00000015296
Gene Symbol: PTPRB
3 Enzyme and pathways 5 Cross references
280 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSBTAG00000037452
Gene Symbol: LOC790312
4 Cross references
130 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSBTAG00000012317
Gene Symbol: PNP
11 Enzyme and pathways 4 Cross references
130 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSBTAG00000000376
Gene Symbol: P2RX3
4 Enzyme and pathways 5 Cross references
284 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSBTAG00000008948
Gene Symbol: P2RX7
9 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSBTAG00000001465
Gene Symbol: P2RY1
12 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSBTAG00000015837
Gene Symbol: P2RY12
12 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSBTAG00000039050
Gene Symbol: P2RY2
10 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSBTAG00000040541
Gene Symbol: P2RY4
8 Enzyme and pathways 5 Cross references
179 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSBTAG00000038737
Gene Symbol: P2RY6
8 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSBTAG00000011534
Gene Symbol: RAMP1
7 Enzyme and pathways 5 Cross references
264 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).